PDF(Pubmed)
Abstract：
Several recent studies have investigated the use of hypofractionated radiotherapy (HFRT) for various cancers. However, HFRT for non-small cell lung cancer (NSCLC) with or without concurrent chemotherapy is not yet widely used because of concerns about serious side effects and the lack of evidence for improved treatment results. Investigations of HFRT with concurrent chemotherapy in NSCLC have usually been performed in single-arm studies and with a small number of patients, so there are not yet sufficient data. Therefore, the Korean Society for Radiation Oncology Practice Guidelines Committee planned this review article to summarize the evidence on HFRT so far and provide it to radiation oncology clinicians. In summary, HFRT has demonstrated promising results, and the reviewed data support its feasibility and comparable efficacy for the treatment of locally advanced NSCLC. The incidence and severity of esophageal toxicity have been identified as major concerns, particularly when treating large fraction sizes. Strategies, such as esophagus-sparing techniques, image guidance, and dose constraints, may help mitigate this problem and improve treatment tolerability. Continued research and clinical trials are essential to refine treatment strategies, identify optimal patient selection criteria, and enhance therapeutic outcomes.
摘要：
最近的几项研究已经调查了在各种癌症中使用大分割放射治疗（HFRT）。然而,由于担心严重的副作用和缺乏改善治疗结果的证据，有或没有同步化疗的非小细胞肺癌（NSCLC）的HFRT尚未广泛使用。HFRT与NSCLC同步化疗的调查通常在单臂研究中进行，并与少数患者。所以还没有足够的数据。因此,韩国放射肿瘤学学会实践指南委员会计划这篇综述文章总结到目前为止关于HFRT的证据,并提供给放射肿瘤学临床医师.总之,HFRT已经证明了有希望的结果，审查的数据支持其治疗局部晚期NSCLC的可行性和相当的疗效.食管毒性的发生率和严重程度已被确定为主要问题，特别是在处理大部分尺寸时。Strategies,比如食道保留技术，图像指导,和剂量限制，可以帮助缓解这个问题，提高治疗的耐受性。持续的研究和临床试验对于完善治疗策略至关重要，确定最佳患者选择标准，并提高治疗效果。
